Interventions for Reading Disabilities in NF1

Learn more about:
Related Clinical Trial
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Toxicity of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Mechanism of Action of Transcranial Direct Current Stimulation in Neurofibromatosis Type 1 Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1 Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial Pilot Randomized Control Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1 Open Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1 Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Medical Treatment of “High-Risk” Neurofibromas Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs) Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Treatment of NF1-related Plexiform Neurofibroma With Trametinib Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas Neurofibromatosis Type 1 Brain Tumor Genetic Risk Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I Reliability of Functional Outcome Measures in Neurofibromatosis 1 Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach. Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) Quality of Friendships in Children With Neurofibromatosis Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1) MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Interventions for Reading Disabilities in NF1 Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain Neurobiology and Treatment of Reading Disability in NF-1 From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1) Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1 Study About Annoucement of the Diagnosis of Neurofibromatosis 1 in de Novo Forms MicroRNAs in Patients With Neurofibromatosis Type 1 Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas Stem Cells in NF1 Patients With Tumors of the Central Nervous System Function of the Pigment Epithelium in Patients With Type 1 Neurofibromatosis NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) Internet Support Group for Parents of a Child With Neurofibromatosis Type 1 Reading Disability in Children With NF1 Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients Functional Imaging and Reading Deficit in Children With NF1 Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1 Effect of Lamotrigine on Cognition in NF1 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia Non-invasive Stimulation in Neurofibromatosis Type 1 Modifying Genes in Neurofibromatosis 1 Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 Spinal Abnormalities in Neurofibromatosis Type 1 (NF1) Neurofibromatosis Type 1 Patient Registry Frameshift Peptides of Children With NF1 Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem

Brief Title

Interventions for Reading Disabilities in NF1

Official Title

Neurobiology and Treatment of Reading Disability in NF1

Brief Summary

      Neurofibromatosis Type 1 (NF1) is a common genetic disorder that is associated with a four
      times greater risk of learning disabilities, including reading disabilities, and a deficiency
      of neurofibromin - a protein important in a signaling pathway that regulates learning and
      memory. Our previous work (NS49096) demonstrated that school-age children with NF+RD can
      respond to standard phonologically-based reading tutoring originally developed to treat
      reading disability in the general population. Combining our work with that by other
      researchers suggesting that a medication (Lovastatin) may counteract the effects of the
      deficient neurofibromin, and possibly ameliorate learning disabilities in NF1, the
      investigator propose to examine the synergistic effects of medication plus reading tutoring.
    

Detailed Description

      Neurofibromitosis Type 1 (NF1) is a common autosomal dominant neurocutaneous syndrome. The
      most common concern of NF1 is learning disabilities (LDs). Approximately half of children
      with NF1 have LDs, the most common of which are reading disabilities (RDs).The purpose of
      this research is to gain a deeper understanding of the characteristics and treatment of RDs
      in NF1.

      The Investigator will evaluate four different groups (see list below) to determine if there
      are differential outcomes in these groups of children with NF+RD. The first two groups will
      consist of NF1 patients, and the second two groups will consist of participants with RDs but
      without NF1.

        1. Reading tutoring program and a medication called Lovastatin (NF1 patients)

        2. Reading tutoring program and no Lovastatin (placebo) (NF1 patients)

        3. Reading tutoring program (RD participants)

        4. Other Academic "Sham" tutoring (eligible to receive reading tutoring after study
           participation is complete) (RD participants)
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Woodcock Johnson Tests of Achievement IV


Condition

Neurofibromatosis Type 1

Intervention

Lovastatin

Study Arms / Comparison Groups

 NF1: Lovastatin + reading tutoring
Description:  Participants (NF-1 patients) will receive 20mg of Lovastatin per day for the first two weeks, the dose will be escalated 40 mg for the remaining 11 weeks.
And one week of intensive, one-on-one reading tutoring intervention

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

120

Start Date

November 2016

Completion Date

July 2022

Primary Completion Date

May 2022

Eligibility Criteria

        Inclusion Criteria:

        This study will be open to all English speakers who meet eligibility criteria regardless of
        race, gender, minority or socioeconomic status. Inclusion criteria to be met are listed
        below:

          1. Individuals ages 8-20 (all participants)

          2. Documented NF-1 (NF patients only)

          3. If female, participant is post-menarche (NF patients only)

          4. If male, participant has reached Tanner Stage 2 (NF patients only)

          5. Participant able to swallow capsule (NF patients only, may be confirmed via
             swallowability test, described below)

          6. Participant's English is sufficient for school (all participants)

          7. Participant must either answer "yes" to question A, or answer "yes" to at least 2
             items for questions B-D listed below:

        A. Has your child ever been diagnosed with a reading disability? B. Did your child have
        trouble learning how to "sound out" words? C. Have you (parent) ever been concerned about
        your child's reading ability? D. Did the school or teacher ever express any concerns about
        your child's reading ability? Swallowability Assessment: We may ask patients to perform a
        capsule swallowability assessment prior to enrollment. We will ask subjects to attempt to
        swallow an empty capsule, matching the same size of the Lovastatin 20mg and 40mg capsules
        to be used in the study, to confirm swallowability. Patients will be provided with up to 2
        capsules as needed to successfully perform the swallowability assessment. If the patient is
        unable to swallow the capsule, enrollment in the study may deferred or declined.

        A child will be excluded if he/she meets any of the following criteria, which will be
        determined by initial telephone screening as well as review of medical/developmental
        history prior to and during testing:

          1. Child 7 years of age or less;

          2. known uncorrectable visual impairment;

          3. documented hearing impairment greater than or equal to a 25 dB loss;

          4. medical contraindication to MRI procedures (e.g., metal devices);

          5. any psychiatric, behavioral, or developmental disorder that would preclude active
             participation in in-depth tutoring sessions

          6. Pregnant at time of screening.

          7. Known conditions which are contraindicated to Lovastatin

               1. Hypersensitivity to the medication

               2. Uncontrolled Epilepsy

               3. Metabolic Syndrome X, High Blood Sugar,

               4. Muscle Damage Due to Autoimmunity

               5. Stroke caused by Bleeding in the Brain, Loss of Memory,

               6. Severely Low Blood Pressure

               7. Liver Problems including Abnormal Liver Function Tests

               8. Severe Renal Impairment,

               9. Serious Muscle Damage that may Lead to Kidney Failure,

              10. Recent Operation or significant Injury

              11. Muscle Pain or Tenderness with Increase Creatinine Kinase,

              12. Habit of Drinking Too Much Alcohol

              13. Pregnant or lactating. - Lovastatin is contraindicated during pregnancy and in
                  nursing mothers because it decreases synthesis of cholesterol and other products
                  of the cholesterol biosynthesis pathway that are essential components for fetal
                  development.

        Children who meet criteria for ADHD, Oppositional Defiant Disorder, adjustment disorder,
        and/or mild depression will be eligible as long as they are not taking psychotropic
        medications, with the exception of stimulant medication for ADHD.

        For pilot participants only:

        Criteria for inclusion/exclusion for pilot participants is outlined below. Children who
        meet criteria for ADHD, Oppositional Defiant Disorder, adjustment disorder, and/or mild
        depression will be eligible as long as they are not taking psychotropic medications, with
        the exception of stimulant medication for ADHD.

          1. Children ages 8-17

          2. Participant is a native English speaker

          3. Participant must either answer "yes" to question A, or answer "yes" to at least 2
             items for questions 2-4 listed below:

        A. Has your child ever been diagnosed with a reading disability? B. Did your child have
        trouble learning how to "sound out" words? C. Have you (parent) ever been concerned about
        your child's reading ability? D. Did the school or teacher ever express any concerns about
        your child's reading ability?

        A child will be excluded if he/she meets any of the following criteria, which will be
        determined by initial telephone screening as well as review of medical/developmental
        history prior to and during testing:

          1. Children 7 years of age or younger

          2. previous diagnosis of Intellectual Disability;

          3. known uncorrectable visual impairment;

          4. documented hearing impairment greater than or equal to a 25 dB loss;

          5. medical contraindication to MRI procedures (e.g., metal devices);

          6. known IQ below 70;

          7. a pervasive developmental disorder; and

          8. any known neurologic pathology, including epilepsy, spina bifida, cerebral palsy,
             traumatic brain injury, optic gliomas, and brain tumors (other than UBOs).

          9. Comorbid severe psychiatric disorders will also be excluded.
      

Gender

All

Ages

8 Years - 20 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Laurie Cutting, PhD, 615-875-5534, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT02964884

Organization ID

161159

Secondary IDs

1R01HD089474-01

Responsible Party

Principal Investigator

Study Sponsor

Vanderbilt University

Collaborators

 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Study Sponsor

Laurie Cutting, PhD, Principal Investigator, Vanderbilt University Medical Center


Verification Date

January 2021